Allopurinol 100 mg tablet
Public data on allopurinol from CMS and FDA: what pharmacies have paid for it, how many generic applications FDA has approved, and whether it appears in FDA's shortage or recall records.
NADAC per unit, monthly
ALLOPURINOL 100 MG TABLETShow as table
| Month | NADAC per unit ($) |
|---|---|
| 2013-11 | 0.02933 |
| 2014-02 | 0.03059 |
| 2014-05 | 0.02914 |
| 2014-08 | 0.02806 |
| 2014-11 | 0.11678 |
| 2015-02 | 0.14926 |
| 2015-05 | 0.14599 |
| 2015-08 | 0.17838 |
| 2015-11 | 0.16242 |
| 2016-02 | 0.17431 |
| 2016-05 | 0.16393 |
| 2016-08 | 0.15836 |
| 2016-11 | 0.15239 |
| 2017-02 | 0.12963 |
| 2017-05 | 0.13096 |
| 2017-08 | 0.12213 |
| 2017-11 | 0.12754 |
| 2018-02 | 0.10907 |
| 2018-05 | 0.09106 |
| 2018-08 | 0.10301 |
| 2018-11 | 0.08585 |
| 2019-02 | 0.07595 |
| 2019-05 | 0.07421 |
| 2019-08 | 0.07676 |
| 2019-11 | 0.08011 |
| 2020-02 | 0.07530 |
| 2020-05 | 0.07728 |
| 2020-08 | 0.06894 |
| 2020-11 | 0.06540 |
| 2021-02 | 0.06230 |
| 2021-05 | 0.06413 |
| 2021-08 | 0.06105 |
| 2021-11 | 0.06047 |
| 2022-02 | 0.05727 |
| 2022-05 | 0.05375 |
| 2022-08 | 0.04770 |
| 2022-11 | 0.05017 |
| 2023-02 | 0.04828 |
| 2023-05 | 0.05012 |
| 2023-08 | 0.05183 |
| 2023-11 | 0.04922 |
| 2024-02 | 0.04944 |
| 2024-05 | 0.04013 |
| 2024-08 | 0.04194 |
| 2024-11 | 0.04088 |
| 2025-02 | 0.03964 |
| 2025-05 | 0.04264 |
| 2025-08 | 0.04110 |
| 2025-11 | 0.03771 |
| 2026-02 | 0.03530 |
| 2026-05 | 0.03320 |
| 2026-08 | 0.03229 |
| 2026-11 | 0.03118 |
Source: CMS NADAC weekly files, generic rows, monthly median of weekly averages · data as of 2026-11. Figures can change and may contain errors in the source data. Check the original source before relying on them.
Recall records mentioning allopurinol
openFDA enforcement records, by year reported.
| 2024 | 2 |
| 2023 | 2 |
| 2020 | 1 |
| 2015 | 1 |
| 2014 | 1 |
7 records since 2012. A record is one product or lot, not one recall event. Combination products that contain allopurinol are included.
What these numbers mean
NADAC is what retail pharmacies pay on average to buy the drug, published by CMS. It does not include rebates and is not what you pay at the counter. ANDA counts include all strengths and forms and applications whose products are now discontinued.
Most recent recall records
Not health advice. GxRadar is for general information only. Nothing here is medical, pharmacy, legal or financial advice. Do not start, stop or change any medicine based on this site. Talk to your pharmacist or prescriber about your own situation.
Articles that mention allopurinol
5 GxRadar articles cite or discuss this drug.
The generics that cost pharmacies more than they did in 2014
Most generics in GxRadar's 47-drug basket got cheaper. Seven cost pharmacies more than in January 2014, led by furosemide at 2.8 times its 2014 price. What federal cost and shortage data show, drug by drug.
Scored tablets and what the label says about them
Since 2013, FDA has reserved the phrase "functional scoring" for tablets tested to split evenly. Where that wording appears on a prescription label, what sits behind it, and how often it shows up in FDA's data.
The generic price spikes of 2013 to 2015
Generic prices fell overall in the early 2010s, yet 315 established generics at least doubled in price. What GAO and HHS investigators found, what CMS price data show, and what Congress changed.
Pill imprint codes and the 1993 rule behind them
Since September 1995, nearly every US tablet and capsule must carry a code identifying the drug, its strength and its maker. What 21 CFR 206 requires, who is exempt, and where imprint data live now.
The 'to be discontinued' entries on FDA's shortage list
FDA listed 161 drugs as to be discontinued in October 2026, more than twice its current shortages. Most are one maker's exit from one product, and discontinuations rarely start a shortage on their own.